Profound Medical Corp(PROF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:45 PM ET (Korea 11/7 06:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.93 | Insider Own | 3.05% | Shs Outstand | 36.6M | Perf Week | 9.74% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | 27.99% | Insider Trans | - | Shs Float | 35.4M | Perf Month | 4.34% |
| Enterprise Value | 0.24B | PEG | - | EPS next Q | -0.23 | Inst Own | 45.52% | Short Float | 4.4% | Perf Quarter | -1.77% |
| Income | -0.03B | P/S | 11.15 | EPS this Y | 38.77% | Inst Trans | 0.23% | Short Ratio | 7.75 | Perf Half Y | 5.26% |
| Sales | 0.02B | P/B | 6.21 | EPS next 5Y | 61.57% | ROA | -64.68% | Short Interest | 1.56M | Perf YTD | -8.39% |
| Book/sh | 1.16 | P/C | 7.9 | EPS past 3/5Y | -0.76% -2.41% | ROE | -87.04% | 52W High | -19.44% ($8.95) | Perf Year | 23.25% |
| Cash/sh | 0.91 | P/FCF | - | Sales past 3/5Y | 34.06% 17.12% | ROIC | -71.79% | 52W Low | 50.21% ($4.80) | Perf 3Y | -23.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.1% | Gross Margin | 73.86% | Volatility(W/M) | 10.35% 7.17% | Perf 5Y | -36.19% |
| Dividend TTM | - | EV/Sales | 10.05 | Sales Y/Y TTM | 65.25% | Oper. Margin | -145.08% | ATR (14) | 0.47 | Perf 10Y | -3.08% |
| Dividend Ex-Date | - | Quick Ratio | 3.7 | EPS Q/Q | 20.3% | Profit Margin | -137.51% | RSI (14) | 64.37 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.54 | Sales Q/Q | 85.86% | SMA20 | 14.11% ($6.32) | Beta | 0.74 | Target Price | $11.28 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/11/5 | SMA50 | 15.64% ($6.23) | Rel Volume | 1.6 | Prev Close | $6.88 |
| Employees | 162 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -9.37% 11.45% | SMA200 | 8.47% ($6.65) | Avg Volume(3M) | 0.20M | Price | $7.21 |
| IPO | 2016/6/9 | Option/Short | Yes/Yes | Trades | 2434 | Volume | 322,390 | Change | 4.8% |
Profound Medical is a medical device company with a non-invasive prostate tissue ablation technology based on magnetic resonance imaging (MRI) guidance. Its flagship product, TULSA-PRO, is a system that combines robotic control with artificial intelligence to treat prostate conditions, taking a differentiated approach in the field of urology. The company is a micro-cap that is expanding its global installed base and moving into a growth phase.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded more than usual. That is 160% of its average volume.
PROF has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +38.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,115. Peers typically go for $129.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -36.2%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #71 of 140 in the industry
Based on market cap of $263M.
CLPT#69 ClearPoint Neuro Inc $276M PER - 
INFU#70 InfuSystem Holdings Inc $273M PER 30.4 PROF#71 Profound Medical Corp $263M PER - 
TMCI#72 Treace Medical Concepts Inc $262M PER - 
LAB#73 Standard BioTools Inc $251M PER - 
FAQ
What kind of company is PROF?
PROF belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of PROF?
The market cap of PROF is approximately $263M, ranking 3,776 within its sector.
What is the 52-week high and low for PROF?
PROF has recorded a 52-week high of $8.95 and a low of $4.80.
